摘要
目的:探讨大剂量131I治疗分化型甲状腺癌后131I-SPECT/CT断层融合显像的临床价值。方法:对2008年1月-2010年3月本院221例次术后分化型甲状腺癌大剂量131I治疗后4-7天行131 I全身扫描和病灶部位的131I-SPECT断层加同机CT融合显像,探讨断层融合显像的特点和临床价值。结果:断层融合显像能够获得直观的断层融合显像和三维立体图像,发现颈部转移淋巴节部位更准确、直观,更容易区分术后残余甲状腺与转移淋巴结;发现更多的病灶及更准确的判断病变部位;准确鉴别病灶和生理显影或污染;定位CT可以发现无摄碘功能的病灶。结论:大剂量131I治疗分化型甲状腺癌后行131I-SPET/CT断层融合显像检测131I在体内的分布,从而进行特异性诊断及疗效检测,有重要的临床价值。
Objective：To explore the clinical value of 131I-SPECT/CT fuse imaging in differentiated thyroid carcinoma（DTC） after high-dose 131I treatment.Methods： There were 221 cases who had been diagnosed as DTC after operation from 2008 to 2010,Whole body scan and 131I-SPECT/CT fuse imaging were obtained after 4-7 days of high-dose 131I therapy.Results： 131I-SPECT/CT fuse imaging can obtain the intuitive fuse imaging and three-dimensional image,lymph node metastasis in the neck was found more accurately;and it is more easier to distinguish between residual thyroid with lymph node metastasis;and it helps to find and identify lesions more accurately from physiological uptake or pollution.Conclusion： As a specific diagnosis and curative effect detection method,131I-SPECT/CT fuse imaging has an important clinical value after High-dose 131I treatment in DTC.
出处
《现代肿瘤医学》
CAS
2011年第8期1532-1533,共2页
Journal of Modern Oncology
